This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Cortés-Herández, J Articles by Vilardell-Tarres, M Search for Related Content PubMed PubMed Citation Articles by Cortés-Herández, J Articles by Vilardell-Tarres, M Social Bookmarking                         What's this?

Predictors of poor renal outcome in patients with lupus nephritis treated with combined pulses of cyclophosphamide and methylprednisolone

Department of Internal Medicine, Vall d'Hebron Hospitals, Barcelona, Spain

J Ordi-Ros

Department of Internal Medicine, Vall d'Hebron Hospitals, Barcelona, Spain, ordiros{at}hg.vhebron.es

M Labrador

Department of Internal Medicine, Vall d'Hebron Hospitals, Barcelona, Spain

A Segarra

Department of Renal Medicine, Vall d'Hebron Hospitals, Barcelona, Spain

J L Tovar

Department of Renal Medicine, Vall d'Hebron Hospitals, Barcelona, Spain

E Balada

Department of Internal Medicine, Vall d'Hebron Hospitals, Barcelona, Spain

M Vilardell-Tarres

Department of Internal Medicine, Vall d'Hebron Hospitals, Barcelona, Spain

Lupus nephritis remains a major cause of morbidity and mortality in patients with systemic lupus erythematosus. Although the renal prognosis has improved, the optimal therapeutic regime has not been definitively established, and significant challenges remain in the management of disease progression and recurrent renal relapse. We performed a prospective study to evaluate the outcome of 38 patients with severe lupus nephritis treated with standard cyclophosphamide and methylprednisolone pulse therapy, and to determine the variables associated with poor outcome. Five patients developed end-stage renal disease (ESRD) (13%), 10 (26%) developed persistent proteinuria (>1 g=24 h) and 15 (39%) suffered at least one relapse after 8 years of follow-up. A high chronicity index, interstitial fibrosis (P = 0.04), persistent hypertension (P < 0.0001) and hypocomplementaemia(P = 0.002) after treatment were the major variables associated with ESRD. Tubular atrophy (P = 0.01), persistent hypertension (P = 0.0001) and hypocomplementaemia after treatment (P = 0.0281) were associated with persistent proteinuria. Persistence of anti-dsDNA antibodies and hypocomplementaemia after treatment (P = 0.0118) were associated with renal relapse.

Our data suggest that the group of patients with persistence of hypocomplementaemiaand raised anti-dsDNA antibodies titres are at high risk of renal relapse and may be candidatesfor continuation of immunosuppressive treatment. Patients with persistent proteinuria alone or a high chronicity index are less likely to respond to immunosuppression, and strict control of the hypertension may be the best approach.

Key Words: lupus nephritis • prognostic factors • hypocomplementaemia • cyclophosphamide

Lupus, Vol. 12, No. 4, 287-296 (2003)
DOI: 10.1191/0961203303lu340oa


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				G K Bertsias, J P A Ioannidis, J Boletis, S Bombardieri, R Cervera, C Dostal, J Font, I M Gilboe, F Houssiau, T Huizinga, et al. EULAR points to consider for conducting clinical trials in systemic lupus erythematosus: literature based evidence for the selection of endpoints Ann Rheum Dis, April 1, 2009; 68(4): 477 - 483. [Abstract] [Full Text] [PDF]

				O Traitanon, Y Avihingsanon, V Kittikovit, N Townamchai, T Kanjanabuch, K Praditpornsilpa, J Wongchinasri, K Tungsanga, and S Eiam-Ong Efficacy of enteric-coated mycophenolate sodium in patients with resistant-type lupus nephritis: a prospective study Lupus, August 1, 2008; 17(8): 744 - 751. [Abstract] [PDF]

				G Ferraccioli and G Romano Renal interstitial cells, proteinuria and progression of lupus nephritis: new frontiers for old factors Lupus, June 1, 2008; 17(6): 533 - 540. [Abstract] [PDF]

				G Bertsias, J P A Ioannidis, J Boletis, S Bombardieri, R Cervera, C Dostal, J Font, I M Gilboe, F Houssiau, T Huizinga, et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics Ann Rheum Dis, February 1, 2008; 67(2): 195 - 205. [Abstract] [Full Text] [PDF]

				Y. E. Chen, S. M. Korbet, R. S. Katz, M. M. Schwartz, E. J. Lewis, and for the Collaborative Study Group Value of a Complete or Partial Remission in Severe Lupus Nephritis Clin. J. Am. Soc. Nephrol., January 1, 2008; 3(1): 46 - 53. [Abstract] [Full Text] [PDF]

				F. Burling, J. Ng, H. Thein, J. Ly, M.R. Marshall, and P. Gow Ethnic, clinical and immunological factors in systemic lupus erythematosus and the development of lupus nephritis: results from a multi-ethnic New Zealand cohort Lupus, October 1, 2007; 16(10): 830 - 837. [Abstract] [PDF]

				J. Wang, W. Hu, H. Xie, H. Zhang, H. Chen, C. Zeng, Z. Liu, and L. Li Induction therapies for class IV lupus nephritis with non-inflammatory necrotizing vasculopathy: mycophenolate mofetil or intravenous cyclophosphamide Lupus, September 1, 2007; 16(9): 707 - 712. [Abstract] [PDF]

				W.P. de Castro, J.V. Morales, M.B. Wagner, M. Graudenz, M.I. Edelweiss, and L.F. Goncalves Hypertension and Afro-descendant ethnicity: a bad interaction for lupus nephritis treated with cyclophosphamide? Lupus, September 1, 2007; 16(9): 724 - 730. [Abstract] [PDF]

				L. Martinez-Lostao, J. Ordi-Ros, E. Balada, A. Segarra-Medrano, J. Majo-Masferrer, M. Labrador-Horrillo, and M. Vilardell-Tarres Activation of the signal transducer and activator of transcription-1 in diffuse proliferative lupus nephritis Lupus, July 1, 2007; 16(7): 483 - 488. [Abstract] [PDF]

				H. M. Bastian, G. S. Alarcon, J. M. Roseman, G. McGwin Jr, L. M. Vila, B. J. Fessler, J. D. Reveille, and for the LUMINA study group Systemic lupus erythematosus in a multiethnic US cohort (LUMINA) XL II: factors predictive of new or worsening proteinuria Rheumatology, April 1, 2007; 46(4): 683 - 689. [Abstract] [Full Text] [PDF]

				E. M. Ginzler, M. A. Dooley, C. Aranow, M. Y. Kim, J. Buyon, J. T. Merrill, M. Petri, G. S. Gilkeson, D. J. Wallace, M. H. Weisman, et al. Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis. N. Engl. J. Med., November 24, 2005; 353(21): 2219 - 2228. [Abstract] [Full Text] [PDF]